DTDeepak Narayan Tayade

Deepak Narayan Tayade

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Deepak Narayan Tayade has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Bhavna Pramod Joshi

    Department of Community Medicine, MGM Medical College, Chhatrapati Sambhajinagar, Maharashtra, India

    2 shared publications
  • Abhishek Dhawan

    Department of Community Medicine, MGM Medical College, Chhatrapati Sambhajinagar, Maharashtra, India

    1 shared publication
  • Anand Kawade

    Department of Pediatrics, KEM Hospital Research Centre, Pune, India

    1 shared publication
  • Andrea Anthony Almeida

    Department of Community Medicine, MGM Medical College, Chhatrapati Sambhajinagar, Maharashtra, India

    1 shared publication
  • Anurag Agarwal

    Department of Pediatrics, Maulana Azad Medical College & Associated Hospitals, New Delhi, India

    1 shared publication
  • Avinash Gawande

    Department of Pediatrics, Government Medical College and Hospital, Nagpur, India

    1 shared publication

Latest Publications

  • Open Access

    Development and assessment of “college student to community strategy” for enhancing tuberculosis case detection

    by Bhavna Pramod Joshi, Deepak Narayan Tayade, Shobha Bansi Salve, Andrea Anthony Almeida, Abhishek Dhawan

    BACKGROUND: Tuberculosis (TB) elimination is the top-most public health priority for India. Taking into account the dire need to enhance the detection of TB cases, an innovative model was developed and implemented. AIM: The aim is to develop and assess “college student to community strategy” for enhancing TB case detection. MATERIAL AND METHODS: A quasi-experimental study was conducted in seven different nonmedical degree colleges. A total of 134 students participated in this study. Information, education, and communication (IEC) sessions describing the epidemiology, presumptive case definition, control, and prevention of TB were conducted. Pretest and posttest were administered to capture knowledge about TB, including identification of presumptive TB cases. Data were analyzed with SPSS V. 25.0. RESULTS: A total of 134 participants were included in this study. Only 108 (80.6%) participants were aware of TB before the IEC session. There was a statistically significant difference in knowledge about transmission, symptoms, diagnosis, treatment, and prevention of TB before and after IEC activity. 118 (88.06%) participants felt confident regarding presumptive TB case detection. Two participants and three close contacts having presumptive TB symptoms were linked to the TB care pathway. CONCLUSION: College students who are equipped with the presumptive TB case detection knowledge can be instrumental in diagnosing the hidden burden of TB in the community. This will detect additional cases along with routine case detection through the National Tuberculosis Elimination Program.

  • Open Access

    A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants

    by Hitt Sharma, Sameer Parekh, Pramod Pujari, Sunil Shewale, Shivani Desai, Anand Kawade, Sanjay Lalwani, M. D. Ravi, Veena Kamath, Jagannath Mahopatra, et al.

    A fully liquid hexavalent containing Diphtheria (D), Tetanus (T) toxoids, whole cell Pertussis (wP), Hepatitis B (Hep B), type 1, 2, 3 of inactivated poliovirus (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (DTwP-HepB-IPV-Hib vaccine, HEXASIIL®) was tested for lot-to-lot consistency and non-inferiority against licensed DTwP-HepB-Hib + IPV in an open label, randomized Phase II/III study. In Phase III part, healthy infants received DTwP-HepB-IPV-Hib or DTwP-HepB-Hib + IPV vaccines at 6, 10 and 14 weeks of age. Blood samples were collected prior to the first dose and 28 days, post dose 3. Non inferiority versus DTwP-HepB-Hib + IPV was demonstrated with 95% CIs for the treatment difference for seroprotection/seroconversion rates. For DTwP-HepB-IPV-Hib lots, limits of 95% CI for post-vaccination geometric mean concentration ratios were within equivalence limits (0.5 and 2). Vaccine was well-tolerated and no safety concerns observed.Clinical Trial Registration – CTRI/2019/11/022052